Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Prostatic Neoplasms 48Prostatic Neoplasms, Castration-Resistant 3Non-metastatic Castration-resistant Prostate Cancer 3Adenocarcinoma 3Urogenital Neoplasms 2Salivary Gland Neoplasms 2Prostatic Diseases 2Neoplasms 2Neoplasm Metastasis 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Castration-resistant Prostate Cancer 2Male Urogenital Diseases 2Bulbo-Spinal Atrophy, X-Linked 2Biochemically Recurrent Prostate Cancer 2Urogenital Diseases 1Triple Negative Breast Neoplasms 1Sleep Initiation and Maintenance Disorders 1Refractory or Relapsed Solid Tumors 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Neoplasms by Site 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1High-Risk Localized Prostate Cancer 1Granulosa cell tumor of the ovary 1Genital Diseases, Male 1Fatigue 1Depression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Injections 13pembrolizumab 10tislelizumab 9toripalimab 6atezolizumab 4Nivolumab 4Carboplatin 3trastuzumab deruxtecan 2olaparib 2lenvatinib 2Pemetrexed 2Paclitaxel 2Oxaliplatin 2Gemcitabine 2Fluorouracil 2Docetaxel 2Cyclophosphamide 2Cisplatin 2Cetuximab 2Bevacizumab 2zimberelimab 1talazoparib 1spartalizumab 1sotorasib 1serabelisib 1penpulimab 1niraparib 1nedaplatin 1mirdametinib 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumor × darolutamide × 1 year × Clear all
NCT06220864 2026-04-14

SNV1521 in Participants With Advanced Solid Tumors

Synnovation Therapeutics, Inc.

Phase 1 Recruiting
400 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡